Chairman Ofir Levi resigns from Vallon board; stays as consultant for 12 months at $22,500/quarter

GRI Bio, Inc.

Ofir Levi resigned as Board member and Chairman effective March 28, 2022, for personal reasons.
Levi enters 12-month consulting agreement for $22,500 per quarter; unvested options vested immediately.
Vested options remain exercisable during consulting term and 90 days thereafter.
Resignation not due to any disagreement with management or operations.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ofir Levi

Chairman of the Board

GRI · GRI Bio, Inc.

Effective: 2022-03-28
Filed: March 30, 2022, 7:59 PM ET

On March 28, 2022, Ofir Levi resigned as a member of the Board of Directors (the “Board”) of Vallon Pharmaceuticals, Inc. (the “Company”) and as Chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ofir Levi resigned as Chairman of the Board at GRI Bio, Inc..

Action: resigned
Role: Chairman of the Board

Exact text from the filing

On March 28, 2022, Ofir Levi resigned as a member of the Board of Directors (the “Board”) of Vallon Pharmaceuticals, Inc. (the “Company”) and as Chairman of the Board.

View on SEC.gov

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-22-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.